CancerDrs

Lung Cancer clinical trials in Georgia

39 actively recruiting lung cancer trials at 32 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Georgia:
  • Phoebe Putney Memorial Hospital — Albany, Georgia
  • Grady Health System — Atlanta, Georgia
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
  • Emory Decatur Hospital — Decatur, Georgia
  • Emory Johns Creek Hospital — Johns Creek, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Georgia:
  • University Cancer & Blood Center, LLC — Athens, Georgia
  • Emory University School of Medicine- Grady Campus — Atlanta, Georgia
  • Winship Cancer Institute, Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Georgia:
  • Research Site — Athens, Georgia
  • Research Site — Atlanta, Georgia
  • Research Site — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Georgia:
  • CTCA at Southeastern Regional Medical Center — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Georgia:
  • Northwest Georgia Oncology Centers, P.C. — Marietta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Georgia:
  • Memorial University Medical Center /ID# 264081 — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Georgia:
  • University Cancer & Blood Center, LLC — Athens, Georgia
  • Local Institution - 0412 — Augusta, Georgia
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Georgia:
  • Research Site — Marietta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT07128199
Sites in Georgia:
  • City of Hope - Atlanta — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as Fir…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06646276
Sites in Georgia:
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Georgia:
  • Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Georgia:
  • University Cancer and Blood Center LLC — Athens, Georgia
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Northside Hospital — Atlanta, Georgia
  • Northside Hospital - Duluth — Duluth, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in Georgia:
  • Emory University Hospital Midtown — Atlanta, Georgia
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
  • Emory Saint Joseph's Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Georgia:
  • Augusta University Georgia Cancer Center — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…

Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Georgia:
  • Winship Cancer Institute, Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…

Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Georgia:
  • Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Georgia:
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Georgia:
  • Avenzo Therapeutics Recruiting Site — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Local…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07680764
Sites in Georgia:
  • University Cancer & Blood Center, LLC — Athens, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumo…

Sponsor: Molecular Partners AG
NCT ID: NCT07278479
Sites in Georgia:
  • Emory University Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Sponsor: Teligene US
NCT ID: NCT05168566
Sites in Georgia:
  • University Cancer & Blood Center — Athens, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest. Proton therapy is a type of radiation treatme…

Sponsor: Emory University
NCT ID: NCT06008730
Sites in Georgia:
  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
View on ClinicalTrials.gov →

Showing 25 of 39 trials with sites in Georgia. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19